Skip to main content

Guidelines Address RT for Management of HPV-Linked Oropharyngeal Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on June 28, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, June 28, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online June 18 in Practical Radiation Oncology, recommendations are presented for the use of radiation therapy (RT) for management of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).

Danielle N. Margalit, M.D., M.P.H., from Brigham and Women's/Dana-Farber Cancer Center in Boston, and colleagues addressed five key questions on the use of RT for management of HPV-associated OPSCC. Recommendations were based on a systematic review of the literature and predefined consensus-building methodology.

The researchers recommended concurrent cisplatin for patients receiving definitive RT with T3 to 4 disease and/or one node >3 cm, or multiple nodes. Concurrent cetuximab, carboplatin/5-fluorouracil, or taxane-based systemic therapy are conditionally recommended for similar patients ineligible for cisplatin. RT with concurrent cisplatin is recommended for positive surgical margins or extranodal extension in the postoperative setting. For pT1 to 2 disease and a single node ≤3 cm, without other risk factors, observation is conditionally recommended. For patients treated with definitive RT with concurrent systemic therapy, 7,000 cGy in 33 to 35 fractions is recommended; 5,600 to 6,000 cGy is recommended for patients receiving postoperative RT without positive surgical margins and extranodal extension. Intensity modulated RT is recommended over three-dimensional techniques for all patients receiving RT, with reduction in dose to critical organs-at-risk. About three months after definitive RT/chemoradiation, reassessment with positron emission tomography-computed tomography is recommended.

"This updated guideline underscores the importance of tailored radiation strategies that maximize patient survival while minimizing side effects," Margalit said in a statement.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer

FRIDAY, April 18, 2025 -- A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced...

CT Exams in 2023 Projected to Result in 103,000 Future Cancers

THURSDAY, April 17, 2025 -- At current utilization and radiation dose levels, computed tomography (CT) examinations in 2023 were projected to result in about 103,000 future...

Breast Surgery Can Be Omitted After Neoadjuvant Systemic Therapy in Select Patients

FRIDAY, April 11, 2025 -- Omission of breast surgery after neoadjuvant systemic therapy (NST) in select patients with invasive breast cancer may be feasible, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.